Editas Medicine, Inc. announced an amended collaboration with Celgene Corporation under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. Under the terms of the amended agreement, Editas Medicine will receive a payment of $70 million. Under the terms of the amended agreement, Editas Medicine may develop genome editing tools and Celgene will have rights to opt-in to such genome editing tools for development of gene edited alpha-beta T cell therapies.

For each new experimental medicine that Celgene develops and commercializes using opted-into genome editing tools, Celgene will pay Editas Medicine potential future milestone and royalty payments.